Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Osimertinib in Hepatic Impairment
NCT02161770Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- Dec 2014
- Primary completion
- May 2017
- Modality
- Small Molecules
- Countries
- 6
01
Overview
Phase 1, open-label trial of osimertinib in solid tumor (3 arms), sponsored by AstraZeneca. Primary endpoints: Maximum Plasma Concentration at Day 1 and Area Under the Curve at Day 1. Started Dec 2014; status: completed.
02
Drugs
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT02161770.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02161770.